Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790008 | 0.86 | CA2 (0.43) | — | |
| SCHEMBL29267529 | 0.85 | ENPP2 (0.58) | ENPP2PTGS2SMN1; SMN2GPR119RIPK1 | |
| SCHEMBL17394036 | 0.83 | LMNA (0.44) | ENPP2SMN1; SMN2 | |
| SCHEMBL1365908 | 0.83 | ALDH1A1 (0.46) | ENPP2SMN1; SMN2GPR119 | |
| SCHEMBL16734814 | 0.82 | ALDH1A1 (0.44) | SMN1; SMN2 | |
| SCHEMBL1838200 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL6609666 | 0.80 | ALDH1A1 (0.43) | PTGS2SMN1; SMN2GPR119 | |
| SCHEMBL19433226 | 0.79 | CA2 (0.42) | ENPP2 | |
| SCHEMBL15367415 | 0.78 | ENPP2 (0.33) | ENPP2GPR119 | |
| SCHEMBL16734881 | 0.78 | GAA (0.52) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-11458140-B2 | Annulated glycosidase inhibitors | ASCENEURON SA (CH) | 2022-10-04 | — | — | US | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| EP-3672958-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| EP-3395818-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9993484-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-12 | — | — | US | disclosed |
| EP-3177619-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2018-04-25 | — | — | EP | disclosed |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | GAA, GBA3, ENGASE | ENPP2 123/4885PTGS2 4244/4885SMN1; SMN2 1271/4885 |
| US-11458140-B2 | Annulated glycosidase inhibitors | GAA, GBA3, ENGASE | ENPP2 123/4885PTGS2 4244/4885SMN1; SMN2 1271/4885 |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ENPP2 1618/4885PTGS2 2043/4885SMN1; SMN2 291/4885 |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ENPP2 1618/4885PTGS2 2043/4885SMN1; SMN2 291/4885 |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ENPP2 1618/4885PTGS2 2043/4885SMN1; SMN2 291/4885 |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ENPP2 1618/4885PTGS2 2043/4885SMN1; SMN2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.